



[www.nccs.com.sg/Giving](http://www.nccs.com.sg/Giving)



**ANNUAL REPORT**  
**FY2016**

# CONTENTS

CHAIRMAN'S MESSAGE .....	1
BOARD OF TRUSTEES .....	2
ABOUT THE NCC RESEARCH FUND .....	4
PROJECT HIGHLIGHTS .....	6
RUN FOR HOPE .....	8
CANCER PATIENTS SUPPORTING RESEARCH .....	9
FINANCIAL STATEMENT .....	10
DONORS AND FUND ALLOCATION AT A GLANCE .....	11
ACKNOWLEDGEMENT OF DONORS .....	12



Healthcare in Singapore has come a long way in recent years. Already, some are dreaming of how Singapore will celebrate her 100th birthday – almost 50 years away! As we embark on a journey to shape the next 50 years of Singapore's future, several national health concerns need to be addressed, such as our ageing population and the rising trend of cancer incidence. Despite challenges of an uncertain global financial outlook, the gracious outpouring of generosity amidst tough times has proven that many in Singapore actively care for those in less fortunate circumstances.

In June 2017, the National Cancer Centre Singapore will be celebrating the ground-breaking of the new NCCS building. The building is slated for completion by 2022. With four times the current capacity and the addition of the Goh Cheng Liang Proton Therapy Centre, the new National Cancer Centre Singapore will be a beacon of hope for the 1 in 3 Singaporeans facing this devastating illness. We wish to thank Mr Goh Cheng Liang and the Goh Foundation for their vision and generosity to establish the Proton Therapy Centre at the new NCCS.

Alongside the new building and facilities, NCCS is embarking on several new research initiatives centred on proton therapy and cancer immunotherapy. Breakthroughs in medical research lead to improved patient care, and we are confident these new skills will be invaluable when the new NCCS opens its doors in 2022.

Over the years, I've found it heartening to see so many advances in healthcare; especially in cancer treatment. NCCS' research-based approach to cancer treatments has been fruitful – with many strong discoveries this year. As you will read in the pages ahead, cancer immunotherapy has been one of the most promising emerging cancer treatment technologies. We are honoured and grateful for the generosity of all our donors, including AT Capital Charitable Foundation Limited and Lee Kim Tah Holdings Limited, for helping Dr Toh Han Chong launch the world's first FDA Phase III trial of T cell therapy.

With cancer incidence increasing year on year, there is a pressing need to ensure our scientists, doctors and healthcare professionals have the resources required to gain a better understanding of this disease. Your continued generosity and unwavering support help us enable and equip our clinician-scientists for the fight against cancer. Together, we can pursue better treatment options and better outcomes for our community.

We will continue to ensure all gifts, donations and grants are effectively and efficiently managed and used in the areas of greatest need for the advancement of cancer research.

Finally, and on behalf of NCCS, I would like to express my heartfelt appreciation to our donors, partners and supporters. I would also like to acknowledge the steadfast and enthusiastic staff of NCCS, who have worked tirelessly and diligently towards our shared cause.

Thank you all for providing *hope* to our patients.

**Dr Charles Toh Chai Soon**  
Chairman  
NCC Research Fund

# BOARD OF TRUSTEES

## Chairman



**Dr Charles Toh Chai Soon**  
Consultant Cardiologist,  
Charles Toh Clinic

## Members



**Mdm Ho Geok Choo**  
CEO,  
Human Capital (Singapore) Pte Ltd



**Mr Lim Beng Hua**  
Retiree



**Mr Ng Boon Yew**  
Chairman and CEO,  
Raffles Campus Pte Ltd



**Prof Soo Khee Chee**  
Director,  
National Cancer Centre Singapore



**Mr Tan Ng Kuang, Nicky**  
CEO,  
nTan Corporate Advisory Pte Ltd



**Prof Tan Ser Kiat**  
Emeritus Consultant,  
Singapore General Hospital



**Mr George Thia Peng Heok**  
Director,  
Asialnc Pte Ltd

## INVESTMENT COMMITTEE

### Chairman



**Mr Tan Ng Kuang, Nicky**  
CEO,  
nTan Corporate Advisory Pte Ltd

### Members



**Mr Lim Beng Hua**  
Retiree



**Mr Ng Boon Yew**  
Chairman and CEO,  
Raffles Campus Pte Ltd



**Prof Soo Khee Chee**  
Director,  
National Cancer Centre Singapore



**Dr Charles Toh Chai Soon**  
Consultant Cardiologist,  
Charles Toh Clinic

## AUDIT COMMITTEE

### Chairman



**Mr Ng Boon Yew**  
Chairman and CEO,  
Raffles Campus Pte Ltd

### Members



**Mr Kaka Singh**  
Chairman and Senior Partner,  
RSM Chio Lim LLP



**Mr Sim Guan Seng**  
Managing Partner,  
Baker Tilly TFW LLP

## BANKERS

**DBS Ltd, UBS AG, UOB Bank and  
National Australia Bank**

## AUDITOR

**KPMG**

## CAMPAIGN STEERING COMMITTEE

The Campaign Steering Committee is comprised of a dedicated group of volunteers committed to advancing cancer care and research at the National Cancer Centre Singapore (NCCS). Members are advocates and connectors, supporting the fundraising priorities of the NCCS Charity Funds.

### CO-CHAIR

- Mdm Ho Geok Choo, CEO, Human Capital (Singapore) Pte Ltd
- Mr George Thia Peng Heok, Director, Asialnc Pte Ltd

### MEMBERS

- Ms Bianca Cheo, Chief Operating Officer, Mewah International Inc
- Mr Noel Hon, Board Director, Singapore Pools (Pte) Ltd
- Mr Ong Yew Huat, Former Managing Partner, Ernst & Young
- Ms Jenny Setnicker, Director, Business Development, BlackDog TV
- Ms Amy Tee, Managing Director, Credit Suisse AG
- Mr KC Wong

### AMBASSADORS

- Mr Aldric How, Senior Director, Frontier Management Inc
- Mr Alex Tan, CEO, Zico Capital
- Mr Alex Yew, Senior Recruiter, ASEAN, Amazon Web Service

## DEVELOPMENT COMMITTEE

The Development Committee is comprised of a dedicated group of volunteers who oversee the biennial charity dinner and ensure appropriate governance and compliance with fundraising rules.

### CHAIRPERSON

- Mdm Ho Geok Choo, CEO, Human Capital (Singapore) Pte Ltd

### MEMBERS

- Mr Kwee Liong Seen, Executive Director, Pontiac Land Private Limited
- Mrs Annie Chiam, Senior Vice President, Millenia Private Limited, Pontiac Land Group
- Ms Rosemarie Chong, Managing Director, CA Indosuez (Switzerland) SA
- Mr Eric Teng, Advisor, Tecity Group and Tan Chin Tuan Foundation
- Datuk Eng Son Yam, Managing Director, Wan Chung Construction Singapore
- Mr S. Magendiran, Senior Deputy Principal, Student Development, Raffles Institution
- Mr Tan Fuh Gih, Director, Kim Seng Holdings Pte Ltd
- Ms Wong Chien Chien, Managing Director and Chief Operating Officer - Asia Pacific Credit Suisse
- Ms Lynn Ng, Group Director (Policy), Singapore Workforce Development Authority
- Mr Chan Chong Beng, Chairman, Goodrich Global

# ABOUT THE NCC RESEARCH FUND

Established in 2005, the NCC Research Fund serves as the flagship fundraising and grant-making channel of the National Cancer Centre Singapore (NCCS).

The NCC Research Fund fulfils three objectives:

- Providing **Seed Funding** to help our scientists to kick-start worthy and emerging research projects. By doing so, they build a track record and will be able to apply for sustainable competitive grants from government agencies.
- Providing **Bridge Funding** between government grant cycles when the need arises, in order to enable our scientists to work with productive momentum.
- Providing **Advancement Funding** to enhance research-related infrastructural capabilities, hardware, tools and processes.

With cancer accounting for more than one in four deaths in Singapore, NCCS plays a pivotal role in holistic care and multidisciplinary-based treatment of cancer patients. Innovative medicine requires quality research to drive leading patient care. Our clinician-scientists require philanthropic support to drive medical breakthroughs for the benefit of our community.

**We firmly believe that today's research will pave the way for tomorrow's cure.**

Through your generous support of cancer research, we can provide hope to Singaporeans living with cancer.

The NCC Research Fund is registered under the Charities Act as an Institution of Public Character (IPC) with an independent Board of Trustees.

## CHARITY STATUS

- Charity Registration Number: 01897
- Charity Registration Date: 19 August 2005
- Date of Establishment: 6 May 2005

## DISCLOSURES OF CONFLICT OF INTEREST

The NCC Research Fund maintains a Conflict of Interests policy to assist the Board of Trustees, employees, consultants, vendors, volunteers and major donors of the The NCC Research Fund to identify and manage situations that may present potential conflict of interest. The policy includes requirements for the declaration of potential conflicts, procedures for managing such conflicts, and documentation required if such conflicts occur.


## FUNDING SOURCES

The NCC Research Fund raises funds through the generosity of individuals, foundations and corporations in support of research projects, to meet the objectives of the Fund. The funding of all projects is approved by the Trustees or designated Trustees.

## GRANT MONITORING COMMITTEE

The Grant Monitoring Committee assists the Board in grant related matters, in particular, the reviewing of progress and/ or final reports for projects supported by the NCC Research Fund to ensure the desired outcomes are achieved as per the grant proposals. The Committee determines and makes recommendations to the Board on whether to continue or terminate funding support for awarded projects.

The proceedings of all Committee meetings including the summary of submitted progress and/ or final reports, plus comments made by the Committee after reviewing these reports, will be presented to the Audit Committee and to the Board of Trustees for their approval as appropriate.



# PROJECT HIGHLIGHTS



**Associate Professor Toh Han Chong,**  
Deputy Director (Education),  
National Cancer Centre Singapore

## \$3.6M INVESTED IN IMMUNOTHERAPY RESEARCH

In FY2016, the NCC Research Fund was delighted to partner with three visionary donors and investors to establish the Research Programme in Cancer Immunotherapy at NCCS and the Lee Kim Tah Immunotherapy Research Fund in support of Oncology ACP.

Immunotherapy has emerged as one of the most exciting new cancer treatments. In principle, it works by harnessing the body's immune system to fight cancer and brings real hope to cancer patients. Immunology drugs have shown real survival benefit in many cancers.

In Singapore, NCCS is evaluating the use of immunotherapy in cancer. Dr Toh Han Chong was the first clinician-scientist in Singapore to develop and deliver cellular immunotherapy to patients successfully.

Dr Toh and his team have just completed a successful Phase II clinical trial using chemotherapy followed by T cell immunotherapy for advanced nasopharyngeal cancer (NPC) with strong survival results. The international Phase III trial of this treatment in NPC represents the world's first FDA Phase III trial of T cell therapy in any cancer. This ongoing clinical trial is an international first and places NCCS on the world stage.

We are grateful for the generosity of all of our donors including AT Capital Charitable Foundation Limited and Lee Kim Tah Holdings Limited for their incredible commitment to drive immunotherapy research forward in Singapore.

All investments were directed to the NCC Research Fund.



**Dr Hu Jian Cheng,**  
Principal Investigator,  
Division of Cellular & Molecular Research

## GENETIC RESEARCH FURTHERS THE FIGHT AGAINST CANCER

Cancer is a complex disease caused by DNA alterations. Genomic studies have shown that the hyperactivation of Ras/RAF/MEK/ERK signalling by DNA alterations is one of the prominent causes of cancer and responsible for more than 40% of cancer cases.

To block this signalling for cancer therapy, both RAF and MEK inhibitors have been produced and used for clinic treatment. Unfortunately, these drugs have a very limited efficacy and cause severe side effects. This has prompted the team to conduct research for a deeper understanding of the molecular mechanism controlling Ras/RAF/MEK/ERK signalling in cancer cells.

Currently, the team uses advanced molecular biology, biochemistry, and genetics methods to figure out how Ras/RAF/MEK/ERK signalling is hyperactivated by DNA alterations and in turn induces cancer. This leads to the illustration of the regulatory mechanism of Ras/RAF/MEK/ERK signalling and the discovery of some novel targets for drug design. Based on these findings, the next-generation drugs against cancers are being developed. It is hoped that the research will eventually lead to a generation of more effective cancer drugs which could extend patients' lives.

This project was funded by the NCC Research Fund.

“Philanthropic support validates our efforts and encourages our dedicated healthcare professionals to keep doing better, as we look for ways to fight against diseases and make new discoveries to help future generations.”

**- Dr Iain Tan,**  
Senior Consultant Medical Oncologist and Clinician Scientist, NCCS



“After working here for over 24 years, and seeing my mother's fight against cancer, I understand what cancer patients go through. I've been donating to cancer research for almost 10 years, I choose to because I hope that one day, we can all find a cure for cancer.”

**- Ms Gunasundari Subramaniam,**  
Senior Associate, Division of Radiation Oncology, NCCS



# RUN FOR HOPE

Cancer survivors, Team Singapore athletes, and runners of all ages gathered at Marina Bay in the morning of 19 February 2017, for the 24th instalment of Run For Hope. Guest of Honour Mr Chee Hong Tat, Minister of State for Health and Communications & Information, graced the event by flagging off the 10km run, and running the 3.5km leg.

Run For Hope is the longest running and largest cancer run in Singapore. Donations raised are directed to the NCC Research Fund. To date, Run For Hope has had close to 100,000 participants from all over the world, and raised more than \$1.5 million in net proceeds for cancer research at NCCS.



The Run For Hope Committee members with Dr Charles Toh (4th from left) and Prof Soo Khee Chee (4th from right)

“NCCS treats the majority of the cancer patients in the public sector in Singapore. Proceeds raised from the run will go towards conducting clinical trials and research projects. This can help us to continue improving our diagnosis and treatment for patients. Hopefully, this will translate to a rise in cancer survival rates,” said Professor Soo Kee Chee, Director at NCCS.

Patients and survivors from all walks of life stepped up to speak out about their personal experiences with cancer. This year’s advocates inspired the community to run and raise awareness by sharing their individual stories. Breast cancer survivor Ms Kate Wong said,

“I am very thankful to the staff of NCCS. The doctors, nurses and support group have helped me a lot. I think cancer is the best thing that has ever happened to me. It helped me decide to quit my stressful job to stop and smell the roses.”

“It’s been two years since I was diagnosed and each day is a blessing to me. I want to live my life to the fullest and be a role model to those who have cancer. I took part in my first Run For Hope last year and promised I would run every year,” shared Ms Judy Anthony, a cancer survivor. Ms Anthony also spoke with The Straits Times about the support given to her by her friends.

Besides The Straits Times, the event attracted the interest of many TV and Radio media agencies.



▲ Minister Chee Hong Tat with NCCS mascot, Buddie the Badger

◀ Run For Hope Ambassadors, Mr Sng Tiang Kee (left) and Ms Kate Wong



# CANCER PATIENTS SUPPORTING RESEARCH



Photo credit: The Straits Times

This year marks the 12th year since Mr Sng Tiang Kee’s diagnosis of stage four prostate cancer. The octogenarian is a model of confident optimism, even when afflicted with cancer. This is possible due to the careful management of his health by his physician, Dr Ravindran Kanesvaran, together with a multidisciplinary team in NCCS.

The spritely 82-year-old Mr Sng lives a full life. He is a proud grandfather of four, coaches badminton twice a week to children, practices luk tung kuen (a kind of taichi-like exercise) four times a week, learnt to play the ukulele in recent years, and is now a Run for Hope 2017 Ambassador.

“They know I’m a fighter,” said Mr Sng of his family. “They pushed me for the good things – to make sure I follow up with my medicine and exercise regularly. It’s important to have exercise as part of your lifestyle!”

Extracted from SingHealth’s Tomorrow’s Medicine.

“When I was a Primary 5 student in 2005, strange sores and eruptions appeared all over my body. Two years later, I was diagnosed with skin cancer,” says Mr Goh Chang Teck. Chang Teck, now 23, is a cancer survivor and Run for Hope 2017 Ambassador.

It never occurred to Chang Teck, nor his family, that cancer could strike at such a young age. Let alone twice. In 2013, he was about to enlist in the army. His cancer had not only returned, but progressed. He was unfit for duty.

He felt lost, disappointed and guilty. He was unable to pursue his dream of serving Singapore and felt like a burden to his parents.

But thanks to family, friends and NCCS, Chang Teck found hope. Constant encouragement and emotional support gave him strength during his weakest moments. He “realised the extent that people would go to just to see him happy and strong.”

Thanks to the research programmes of NCCS, Chang Teck survived his cancer, twice. He hopes to inspire and encourage people to support cancer research.



# FINANCIAL STATEMENT

FY2016  
\$

## INCOMING RECEIPTS

Donations	
- Tax-Deductible	2,385,688
- Non-Tax-Deductible	79,983
Investment Income	575,488
Investment Gains	919,564
Others	N/A
<b>TOTAL RECEIPTS</b>	<b>3,960,723</b>

## EXPENSES

Direct Charitable Expenses	
- Local	13,795,597
- Overseas	N/A
Operating/Administration Expenses	324,706
Fundraising	5,745
Publicity	1,698
Capital Expenses	N/A
Others	N/A
<b>TOTAL EXPENDITURE</b>	<b>14,127,746</b>

## BALANCE SHEET

<b>Assets</b>	
Tangible Assets	2,001
Accounts Receivable	197,647
Cash & Deposits	53,618,405
Others	10,026
<b>Total Assets</b>	<b>53,828,079</b>

<b>Funds</b>	
General Fund	28,467,934
Building Fund	N/A
Endowment Fund	22,368,033
Designated/Restricted Fund	2,563,322
<b>Total Funds</b>	<b>53,399,289</b>


<b>Liabilities</b>	
Long-Term Liabilities	N/A
Current Liabilities	428,790
<b>Total Liabilities</b>	<b>428,790</b>
<b>TOTAL FUNDS &amp; LIABILITIES</b>	<b>53,828,079</b>

## OTHER INFORMATION


No. of Employees	15
Total Employee Costs	\$579,398

# DONORS AND FUND ALLOCATION AT A GLANCE

## SOURCES OF DONATIONS



## FOR EVERY \$1 WE SPEND





# ACKNOWLEDGEMENT OF DONORS

## \$1,000,000 and above

Lim Kim Tah Holdings Limited

National Cancer Centre of Singapore Pte Ltd

Tessa Therapeutics Pte Ltd

## \$100,000 - \$999,999

Anonymous (2)

AT Capital Charitable Foundation

Chiu Teng Enterprises Pte Ltd

The Late Mrs Irene Bronsveld

Ng Chan Kheng

## \$10,000 - \$99,999

Alltrust International Pte Ltd

Anonymous (8)

Cheng Wai Keung

Climbers Against Cancer

Estate of Hong Ah Choy

Fang Poh Kein

Irene Chong

Keppel Care Foundation

Ng Toh Siong

Ntegrator International Ltd

Regent Singapore

Tan Hiap Tia

Tai Wai Cheng